Spire Wealth Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Spire Wealth Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,000	Closed	-$6K	–	2709
2022 Q2	$6K	Hold	2,000	–	–	﹤0.01%	2104
2022 Q1	$14K	Hold	2,000	–	–	﹤0.01%	1933
2021 Q4	$17K	Hold	2,000	–	–	﹤0.01%	2187
2021 Q3	$15K	Hold	2,000	–	–	﹤0.01%	1978
2021 Q2	$14K	Hold	2,000	–	–	﹤0.01%	2016
2021 Q1	$21K	Buy	+2,000	New	+$21.9K	﹤0.01%	2141

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Spire Wealth Management's JNCE Position: Q3 2022 in Review

Spire Wealth Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2022, closing a stake of 2,000 shares — an estimated $6K sold.

Spire Wealth Management first reported a position in JNCE in Q1 2021 and held it in 6 quarters. The position peaked at $21K in Q1 2021. 102 funds tracked by Wall St. Rank hold JNCE as of Q3 2022.

Spire Wealth Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Spire Wealth Management sold 2,000 Jounce Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $6K.
Spire Wealth Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2021 and held it in 6 quarters.
Spire Wealth Management's Jounce Therapeutics, Inc. Common Stock position peaked at $21K in Q1 2021.
102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Spire Wealth Management's 13F filing for Q3 2022, filed 7 Nov 2022.